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the first half of 3D detection volume, no farther than 30-35 cm away 
from the generator.  
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Purpose/Objective: The aim of this study was to obtain equivalent 
doses to radiosensitive organs when applying high-dose-rate (HDR) 
brachytherapy to a localized prostate carcinoma using 60Co or 192Ir 
sources, and in comparison to external-beam radiotherapy (EBRT). 
Materials and Methods: Monte Carlo (MC) simulations in Geant4 were 
performed using a voxelized phantom described in International 
Commission on Radiological Protection (ICRP) Publication 110, which 
reproduces masses and shapes from an adult reference man defined in 
ICRP Publication 89. Point sources of 60Co or 192Ir with photon energy 
spectra corresponding to those exiting their capsules were placed in 
the center of the prostate. Equivalent doses per clinical absorbed 
dose to the prostate were obtained in several radiosensitive organs. 
Values were corrected to account for realistic source dwell times and 
positions throughout the prostate. This was repeated for a 
homogeneous water phantom to assess the adequacy of a 
homogeneous phantom for HDR dose calculations. Brachytherapy 
doses were compared to reported values from three-dimensional 
conformal radiotherapy (3D-CRT), intensity-modulated radiation 
therapy (IMRT), and proton therapy. 
Results: For the nearest organs considered (bladder, rectum, testes, 
small intestine, and colon), equivalent doses given by 60Co source 
were smaller than from 192Ir. As the distance increased, the more 
penetrating gamma-rays produced by 60Co delivered higher equivalent 
doses. Relative to 192Ir, the dose ratio increased up to a factor 5 for 
the brain. Due to the photoelectric effect and the passage of photons 
through different tissues (bone, air, and lungs), differences between 
the heterogeneous and the water phantom became apparent at 
distances larger than 30 cm. Finally, for the closest organs, equivalent 
doses from the three EBRT modalities were within an order of 
magnitude to equivalent doses deposited by both brachytherapy 
sources. However equivalent doses from brachytherapy were up to 
two orders of magnitude smaller than EBRT for the furthest organs. 
Conclusions: According to physical considerations, 60Co appears 
dosimetrically advantageous over 192Ir sources at close distances, but 
not for the furthest organs. On the other hand, equivalent doses to 
distant healthy organs were lower for brachytherapy than the three 
studied EBRT modalities.  
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Purpose/Objective: Evaluation of feasibility and early tolerance of 
interstitial hyperthermia combined with salvage prostate 
brachytherapy in patients with BGI confirmed local recurrence after 
previous external beam radiotherapy. 
Materials and Methods: Between 16th December 2008 and 25th 
October 2012, in the Centre of Oncology in Cracow, 21 patients with 
biopsy confirmed local recurrence of previously irradiated prostate 
cancer were qualified for salvage HDR brachytherapy of the prostate 
combined with interstitial hyperthermia using BSD500 equipment (BSD 
Medical). 55 hyperthermia procedures had been performed out of 
planned 63 (87,3%). The reason for quitting procedure was failure of 
the hyperthermia equipment in 5 cases and only saddle block 
anaesthesia in 3 patients cases. The aim of the hyperthermia 
treatment was to heat (in asynchronous mode in order to protect the 
urethra) the peripheral zone of the prostate to 41 – 43°C for 60 
minutes. All patients were treated with the brachytherapy dose of 30 
Gy in 3 fractions, 10 Gy each, with 3-week intervals between 
fractions. 3D inverse planning under TRUS control was performed 
using SWIFT or ONCENTRA Prostate ® systems, Nucletron™. 
Results: Combined treatment including interstitial hyperthermia and 
HDR brachytherapy is feasible during the period of standard 
subarachnoid anaesthesia for brachytherapy. Mean therapeutic 
hyperthermia duration was 50 minutes (range 30 – 60). Mean 
temperature in the prostate during the procedure was 41,2°C (range 
38.4 –42.9°C), maximal temperature measured in the prostate was 
41,9°C (range 40.4 – 43,4°C), and mean temperature in the rectum 
was 38,5°C (range 37,1 – 42°C) – 20 measurements in rectum were 
done. The most frequent complications in the first 3 months after 
treatment were: nocturia 3x – 28,5%, 4x and more - 38%, weak urine 
stream, G1 - 52%, G2 - 24%, urinary frequency G1 - 38%, G2 - 24%, 
hematuria G1 - 47,5%, G2 - 9,5%, non-bacterial inflammation of the 
urethral or bladder G1 - 38%, urgency G1-38%, G2 - 5%; perineal, 
penile or abdominal pain G1 - 19% (self limiting usually in 24-48 
hours), residual urine G1 - 19%, G2 – 14%, urinary incontinence G1 - 
14%. In 1 patient rectal complications were observed (G2 – 
hemorrhage). We didn't observe early complications in the degree G3 
and G4. 
Conclusions: Early tolerance of interstitial hyperthermia in 
combination with HDR brachytherapy is good. No early grade 3 or 4 
complications were found in the analysed group of patients.The most 
common mild complications were urination frequency, nocturia, 
hematuria and transient weakening of urine stream.  
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Purpose/Objective: The purpose of this study is to demonstrate the 
feasibility and safety of combining a brachytherapy boost with an 
hypofractionated EBRT regiment in prostate cancer treatment and 
compare it to our current standard approach, toxicity wise. 
Materials and Methods: 1050 patients have been treated with 
brachytherapy boost (HDRBB) in our facility, all of which we 
prospectively cumulated treatment data. At follow-ups, patients 
filled-in forms reporting side effects and IPSS scoring. 157 
intermediate risk patients were treated with our standard 
fractionation scheme (Std) (40-44Gy in 20-22 fractions) plus HDRBB 
(15Gy single fraction). An experimental group of 30 patients (Table 1) 
were treated with (Hypo) (36Gy in 12 fractions) and HDRBB. Both 
groups share similar pre implants caracteristics. 
Results: Median IPSS scores at consultation and at 1, 3, 6, 12 months 
after treatments are reported in Table 2 as compared with the FU 
reports of our experimental group. No GI grade 3 or 4 toxicities were 
reported in the later group. Patients benificite of a reduction in 
treatment course up to 13 days of treatments. 
 
 
  Hypo (n = 30) Std (n = 157)
Age (years) Median (Std dev) 66 (±7,27) 65 (±6,46) 
Initial PSA Median (Std dev) 
≤ 10 
> 10 <20 
3,7(±3,17) 
28 (93%) 
2 (6%) 
5,9 ±3,54) 
121 (77%) 
36 (23)% 
Clinical stage T1C 
T2A 
T2B 
21 (70%) 
7 (23%) 
2 (7%) 
97 (61%) 
36 (23%) 
24 (15%) 
Gleason score  7 7 
Risk group  Int Int 
Hormonal therapy  8 (26,7%) 18 (11,5%) 
Table 1 : Population demographics. 
 
Treatment \ Median 
IPSS score 
pre (Std
Dev) 
1 month
(Std Dev) 
3 
months 
(Std 
Dev) 
6 
months 
(Std 
Dev) 
12 
months 
(Std 
Dev) 
Hypo (n= 30) 4 (± 7,07) 10,5 
(±8,12) 
5 
(±8,13) 
6 
(±5,18) 
8 
(±7,37) 
Std (n=157) 6 (±6,67) 10 
(±7,96) 
7 
(±9,97) 
8 
(±8,48) 
9 
(±7,22) 
Table 2 Median IPSS score evolution prior and post treatment. 
 
Conclusions: Hypofractionated Radiation course plus brachytherapy 
boost for prostate cancer seems to benefit our patients in reducing 
the total lenght of their treatment from 23 days to 13 days. More 
importantly, this new regiment did not increase the GU nor GI 
toxicity.  
   
 
